[go: up one dir, main page]

DE60129278D1 - Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen - Google Patents

Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen

Info

Publication number
DE60129278D1
DE60129278D1 DE60129278T DE60129278T DE60129278D1 DE 60129278 D1 DE60129278 D1 DE 60129278D1 DE 60129278 T DE60129278 T DE 60129278T DE 60129278 T DE60129278 T DE 60129278T DE 60129278 D1 DE60129278 D1 DE 60129278D1
Authority
DE
Germany
Prior art keywords
semp1
dsm
protein
preparation
directed against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60129278T
Other languages
English (en)
Other versions
DE60129278T2 (de
Inventor
Thorsten Hoevel
Stefan Koch
Manfred Kubbies
Olaf Mundigl
Petra Rueger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HOFFMANN LA ROCHE
F Hoffmann La Roche AG
Original Assignee
HOFFMANN LA ROCHE
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60129278(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP00113344A external-priority patent/EP1167387A1/de
Application filed by HOFFMANN LA ROCHE, F Hoffmann La Roche AG filed Critical HOFFMANN LA ROCHE
Application granted granted Critical
Publication of DE60129278D1 publication Critical patent/DE60129278D1/de
Publication of DE60129278T2 publication Critical patent/DE60129278T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60129278T 2000-06-23 2001-06-22 Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen Expired - Lifetime DE60129278T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00113344A EP1167387A1 (de) 2000-06-23 2000-06-23 Anti-SEMP1-Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen
EP00113344 2000-06-23
EP01107799 2001-04-05
EP01107799 2001-04-05

Publications (2)

Publication Number Publication Date
DE60129278D1 true DE60129278D1 (de) 2007-08-23
DE60129278T2 DE60129278T2 (de) 2008-03-20

Family

ID=26071070

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60129278T Expired - Lifetime DE60129278T2 (de) 2000-06-23 2001-06-22 Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen

Country Status (10)

Country Link
US (1) US6627439B2 (de)
EP (1) EP1167389B1 (de)
JP (1) JP3542784B2 (de)
AT (1) ATE366746T1 (de)
AU (1) AU750296B2 (de)
CA (1) CA2348026C (de)
DE (1) DE60129278T2 (de)
DK (1) DK1167389T3 (de)
ES (1) ES2290072T3 (de)
PT (1) PT1167389E (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EP2305836A1 (de) * 2002-08-20 2011-04-06 Millennium Pharmaceuticals, Inc. Zusammensetzungen, Kits und Verfahren zur Identifizierung, Beurteilung, Vorbeugung und Therapie von Gebärmutterhalskrebs
WO2007130646A2 (en) * 2006-05-04 2007-11-15 The Rockefeller University Hcv coreceptor and methods of use thereof
WO2010034812A1 (en) * 2008-09-25 2010-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Monoclonal anti-claudin 1 antibodies for the inhibition of hepatitis c virus infection
CA2800734A1 (en) 2010-05-25 2011-12-01 Universite De Strasbourg Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024157A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of host targeting agents for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
JP6393875B2 (ja) * 2013-02-28 2018-09-26 公益財団法人ヒューマンサイエンス振興財団 抗体
JP2016528221A (ja) * 2013-08-02 2016-09-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 抗クローディン１抗体およびその使用
EP3027207A1 (de) * 2013-08-02 2016-06-08 Institut National de la Santé et de la Recherche Médicale (INSERM) Anti-claudin-1-antikörper zur verwendung bei der behandlung von kolorektalkrebs
EP3070103A1 (de) 2015-03-19 2016-09-21 Institut Hospitalier Universitaire De Strasbourg Monoklonale anti-claudin 1-antikörper zur vorbeugung und behandlung von hepatozellulärem karzinom
EP3821946A1 (de) 2019-11-12 2021-05-19 Université de Strasbourg Monoklonale anti-claudin-1-antikörper zur prävention und behandlung von fibrotischen erkrankungen
CN113455494A (zh) * 2021-05-12 2021-10-01 南京生航生物技术有限公司 一种无血清细胞冻存液及制备方法和制备装置
KR20250004645A (ko) 2022-03-08 2025-01-08 알렌티스 테라퓨틱스 아게 T 세포 가용성을 증가시키기 위한 항-클라우딘-1 항체의 사용
WO2023233364A1 (en) 2022-06-01 2023-12-07 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to treat cholangiocarcinoma
WO2023233363A1 (en) 2022-06-01 2023-12-07 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to treat cholangiopathies
WO2024069009A1 (en) 2022-09-30 2024-04-04 Alentis Therapeutics Ag Treatment of drug-resistant hepatocellular carcinoma
WO2024194471A1 (en) 2023-03-23 2024-09-26 Alentis Therapeutics Ag Biomarker for cancer treatment using anti-claudin-1 antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8901198A (en) 1997-08-06 1999-03-01 Millennium Pharmaceuticals, Inc. Tango-71, tango-73, tango-74, tango-76, and tango-83 nucleic acid molecules and polypeptides
AU8693598A (en) 1997-08-08 1999-03-01 University Of Washington Isolation of a novel senescence-factor gene, p23
JP2002519029A (ja) 1998-06-29 2002-07-02 インサイト・ファーマスーティカルズ・インコーポレイテッド アポトーシス関連分子

Also Published As

Publication number Publication date
AU5007901A (en) 2002-01-03
CA2348026C (en) 2005-06-07
EP1167389A1 (de) 2002-01-02
EP1167389B1 (de) 2007-07-11
DE60129278T2 (de) 2008-03-20
US20020150574A1 (en) 2002-10-17
ES2290072T3 (es) 2008-02-16
ATE366746T1 (de) 2007-08-15
US6627439B2 (en) 2003-09-30
AU750296B2 (en) 2002-07-11
DK1167389T3 (da) 2007-11-12
JP3542784B2 (ja) 2004-07-14
PT1167389E (pt) 2007-09-27
JP2002332300A (ja) 2002-11-22
CA2348026A1 (en) 2001-12-23

Similar Documents

Publication Publication Date Title
DE60129278D1 (de) Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen
DE69724428D1 (de) Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
ATE470714T1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE384792T1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
CY1108545T1 (el) Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
PL392964A1 (pl) Antygen reaktywny wobec surowicy hiperimmunologicznej zastosowanie tego antygenu do produkcji preparatu farmaceutycznego, fragment hiperimmunologiczny antygenu, epitopy pomocnicze antygenu, szczepionka zawierająca antygen reaktywny wobec surowicy hiperimmunologicznej, preparat zawierający przeciwciała, sposób wytwarzania tego preparatu, zastosowanie preparatu do leczenia infekcji gronkowcowych oraz sposób przesiewania
DE60044058D1 (de) Mit entzündlichen darmerkrankungen (ibd) assoziierte mikrobielle antigene und verfahren derer anwendung
ATE382683T1 (de) Monoklonales antikörper gegen das hcv kernantigen
ATE395364T1 (de) Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung
GB2278357B (en) Humanised antibodies directed against A33 antigen
EP1908837A3 (de) Menschliche Rezeptorproteine, zugehörige Reagenzien und Verfahren
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
ATE353335T1 (de) Einkettige antikörper gegen eine p53 mutante
EP1230932A3 (de) Verwendung von Antikörpern zur Vakzinierung gegen Krebs
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.
DE60128452D1 (de) Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
ATE131069T1 (de) Composition comprising at least two different antibodies or fragments thereof.
BR0204612A (pt) Anticorpos monoclonais antinúcleo de hcv
BR1100582B1 (pt) famÍlia de anticorpos modificados, de alta afinidade, para tratamento de cÂncer.

Legal Events

Date Code Title Description
8363 Opposition against the patent